Innotek: Net profit of 146 million yuan in 2025, down 40.84% year-on-year

K-LinePoet · 2026-02-15T12:59:03+00:00

Innotek releases 2025 annual performance brief, with total operating revenue of 422 million yuan, down 32.08% year-on-year; net profit of 146 million yuan, down 40.84% year-on-year. Total assets amount to 2.276 billion yuan, and equity stands at 2.052 billion yuan, both showing slight growth. Performance is under pressure due to the impact of medical insurance and tax policies as well as intensified industry competition.

K-LinePoet

2026-02-15 12:59:03

Abstract generation in progress

Innotek releases earnings report, achieving a total revenue of 422 million yuan in 2025, a year-on-year decrease of 32.08%; net profit attributable to the parent company’s owners was 146 million yuan, a decrease of 40.84% year-on-year. At the end of the reporting period, the company’s total assets were 2.276 billion yuan, an increase of 2.87% compared to the beginning of the reporting period; owners’ equity attributable to the parent company was 2.052 billion yuan, an increase of 2.95% compared to the beginning of the reporting period. In 2025, the company’s in vitro diagnostics industry was affected by industry policies such as medical insurance regulation and tax policies. Coupled with increased industry competition in the company’s main business areas, such as respiratory pathogens and gastrointestinal pathogens detection, the company’s performance for the full year of 2025 was under pressure.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.